ArticleThe oncologist2025
Antibody-drug conjugate (disitamab vedotin) therapy targeting HER2-low or higher advanced extramammary Paget's disease.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Trial
- Treatment Strategies for Extramammary Paget Disease: A Narrative Review of Current Status and Future Directions.Cancers · 2026Review
- Management of Extramammary Paget Disease of the Male Genital Region: A Narrative Review and Two Case Reports.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveMetastatic Extramammary Paget's disease (EMPD) is an extremely rare cancer and has a dismal prognosis. The rarity of metastatic EMPD has made the clinical trial almost unfeasible, thus high-quality retrospective analysis is valuable.
methodsThe electronic medical files of patients with metastatic EMPD treated from Jan 2017 to April 2024 in a tertiary cancer center in China were reviewed, and available tissues were collected for HER2 staining, if possible. Eleven patients were treated with the anti-HER2 antibody-drug conjugate Disitamab vedotin (DV), using doses of 2 mg/kg, once every 3 to 4 weeks. The efficacy and toxicity data were extracted. Key Findings and Limitations: Treatment with the antibody-drug conjugate DV elicited an objective response in 8 of 11 patients (73%), and CEA response in 10 of the 11 patients (91%). The median progression-free interval was 5.5 months. The median overall survival was 21.9 months. This efficacy was accompanied by mild grade 1 or 2 treatment-related toxicity and no grade 3 toxicity. This study is limited by a small sample size, retrospective nature, and inevitable selection bias. Conclusions and Clinical. IMPLICATIONS: Antibody-drug conjugate targeting of HER2 might be an active treatment for metastatic EMPD. We have initiated a clinical trial to confirm it prospectively. IMPLICATION FOR PRACTICE: Metastatic Extramammary Paget's disease (EMPD) is an extremely rare cancer without standard treatment. Treatment with the antibody-drug conjugate DV (an anti-HER2 antibody-drug conjugate) elicited an objective response in 8 of the 11 patients (73%), and CEA response in 10 of the 11 patients (91%). This efficacy was accompanied by mild treatment-related toxicity. Antibody-drug conjugate targeting of HER2 might be an active treatment for metastatic EMPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.